09 September 2026
09 September 2026
Sandoz wants its portfolio to include more than 100 biosimilars by 2040, up from the 13 it has now.
Shifting emphasis from symptoms to biomarkers has bolstered sector confidence in emerging CNS therapies.
The company says its siRNA-based approach could spare lean muscle at an infrequent dosing schedule as obesity outcomes are defined by more than just weight loss.
The UK remains competitive in its science, but experts say more must be done to incentivise investment into Britain as global rivalry mounts.
Quoin has now received two rare paediatric disease designations for its lead asset QRX003.
The designation was based on preliminary clinical evidence from the ongoing SPRINX-1 Phase I/IIa study.
The new research centre is part of Gilead's strategy to advance US research, development and manufacturing through 2030.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
